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Role of protein kinase pathways in IL-i-induced chemoattractant
expression by human mesangial cells. Human mesangial cells produce the
monocyte-specific chemotactic factor monocyte chemoattractant protein-i
(MCP-1) in response to a variety of stimuli, including the pro-inflamma-
tory cytokine interleukin-1j3 (IL-i). The intracellular signals responsible
for mediating the effects of IL-i on MCP-i expression in human mesangial
cells have not been defined. Evidence from other types of cells suggests
that protein kinases are involved in MCP-i gene regulation. We investi-
gated the role of protein kinase pathways in mediating IL-i-induced
MCP-i expression. Activation of protein kinase C (P1(C) by phorbol esters
or diacyglycerol up-regulated mesangial MCP-i message and bioactivity in
a fashion similar to IL-i. However, while inhibition of PKC activity
completely blocked phorbol-induced MCP-1 up-regulation, induction by
IL-i was not prevented. Inhibitors of cyclic AMP (cAMP)-dependent
protein kinase (PKA) also failed to block IL-i-induced MCP-i expression.
Furthermore, increasing intracellular cAMP and activating PKA attenu-
ated basal MCP-i mRNA levels by 82% and blocked IL-i induced MCP-i
expression by 88%. Finally, the role of protein tyrosine kinases was
studied. The structurally distinct protein tyrosine kinase (PTK) inhibitors
genistein, herbimycin A, and tyrphostin each caused a dose-dependent
inhibition of the effects of IL-i on mesangial MCP-1 activity. IL-i treatment
of mesangial cells resulted in the up-regulation of three tyrosine phospho-
proteins with apparent molecular masses between 40 and 62 kD. These results
suggest that the effects of IL-i on MCP-i expression are not mediated
through PKC or cAMP-PKA, but may be transduced through PTKs.
The pro-inflammatory cytokine interleukin-1 (IL-i) has been
implicated in the pathogenesis of glomerular injury in several
forms of experimental and human glomerulonephritis [reviewed
in 1, 2]. IL-i has multiple effects on intrinsic glomerular cells [1,
2]. Recently, it has been shown that IL-i is a potent inducer of the
monocyte specific chemotactic factor monocyte chemoattractant
protein-i (MCP-1) in cultured human mesangial cells [3, 4].
Although the in vivo significance of MCP-1 remains unknown, we
and others have postulated that it may be an important factor in
recruiting monocytes to the glomerulus during renal disease, thus
enhancing glomerular inflammation and injury. Since IL-i has
been detected in glomeruli from animals and patients with
glomerulonephritis [1, 2], it may serve as an in vivo signal for
activation of mesangial MCP-i production. The signal transduc-
tion pathways used by IL-i to induce MCP-1 expression in
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mesangial cells are unknown. Understanding these regulatory
pathways may suggest interventions to abrogate renal inflammation.
Several lines of evidence support a role for protein kinases in
regulating MCP-i expression. Using endothelial cells, the se-
quence for the human MCP-1 gene has been defined [51. This
report demonstrated that the 5'-flanking region of the MCP-1
gene has a phorbol ester response element [5]. This putative
regulatory sequence may be functionally important since protein
kinase C (PKC) activation by phorbol esters does induce MCP-1
in cultured endothelial and synovial cells [5—7]. The promoter
region of the MCP-1 gene also contains a sequence that could
bind the transcription activating protein NF-KB [5]. Biologically
active NF-KB is thought to be derived from an inactive precursor
after the phosphorylation and dissociation of an inhibitor element
[8]. Using leukocyte cell lines, cyclic AMP (cAMP)-dependent
protein kinase (PKA) has been shown to activate NF-KB [9]. The
recent observation that cAMP can induce MCP-i in certain types
of cells is consistent with this pathway [7, 10].
The signal transduction pathways activated by IL-i have not
been fully characterized. In some lymphocyte cell lines, cAMP-
PKA or PKC may act as second messengers for IL-i [9, 11—13],
but in other cell types, including mesangial cells, the role of these
kinase systems is unresolved [2, 14]. For example, it has recently
been shown that although cAMP may mimic some actions of IL-i
in mesangial cells, it does not mediate its effects [15]. Additionally,
treating mesangial cells with IL-i did not result in phosphoryla-
tion of a putative PKC substrate [2] or increase membrane bound
PKC [16]. Similar results were obtained with IL-i-conditioned
human fibroblasts [17]. IL-i has, however, been shown to stimu-
late protein tyrosine phosphorylation in mesangial cells [18] and
fibroblasts [17], suggesting the possibility that a protein tyrosine
kinase (PTK) may be a second messenger for the IL-i signal.
The current studies were undertaken to investigate the role of
PKC, cAMP-PKA, and PTKs in mediating IL-i-induced MCP-1
expression in human mesangial cells. Our data indicate that while
MCP-1 can be induced by PKC activation, this alone does not
account for the effects of IL-i. Additionally, IL-i does not appear
to act through a cAMP-PKA pathway. Evidence is provided that
PTKs may play a role in the enhanced expression of MCP-1
activity by mesangial cells after IL-i treatment.
Methods
Human mesangial cell cultures
Mesangial cells were obtained as the cellular outgrowths of
collagenase-treated human glomeruli isolated from kidneys
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unsuitable for transplantation. The isolation and characterization
protocols used in our laboratory have been described elsewhere
[3]. In this study mesangial cells from six different donors were
used. Mesangial cells were used between passage 5 and 10 and
were grown to confluence in RPMI 1640 tissue culture media
(GIBCO, Grand Island, New York, USA), supplemented with
10 mrvi HEPES, 2 mM 1-glutamine, penicillin/streptomycin (100
U/mi), and 20% FCS (all from GIBCO). Cells were grown in
75-cm2 tissue culture flasks for RNA isolation (Corning, Corning,
New York, USA) or 24-well tissue culture plates (Linbro,
McLean, Virginia, USA) for chemotaxis assays. Before condition-
ing cells with cytokines, inhibitors, or agonists, the cells were
washed three times with RPMI 1640 containing 0.25% BSA
(Sigma Chemical Co., St. Louis, Missouri, USA). All subsequent
incubations were carried out in RPMI 1640 + 0.25% BSA. At the
end of all experiments cells were exposed to 0.05% trypsin in 0.53
mM EDTA (GIBCO) and counted in a hemocytometer. Condi-
tioned supernatants to be assayed for chemotactic activity or
antigenic MCP-1 were centrifuged to remove debris and subse-
quently frozen.
Mesangial cell conditioning
In these experiments mesangial cells were treated with a variety
of reagents to alter intracellular protein kinase activity before IL-i
stimulation. Total cellular RNA and conditioned tissue culture
supernatants were then harvested (see below), and the effects of
these agents on MCP-1 expression were examined. All reagents
were diluted in RPMI 1640 + 0.25% BSA to achieve the
appropriate concentrations. Control monolayers were treated
only with RPMI 1640 + BSA; in experiments using reagents that
were solubilized in an organic solvent (for example, DMSO,
ethanol) the media for control monolayers contained these sol-
vents in the same final concentrations as the experimental mono-
layers. For cytokine conditioning, human rIL-1/3, (sp. act. 5 X 108
U/mg, Genzyme, Cambridge, Massachusetts, USA) was used at a
concentration of 0.6 ng/ml, previously determined to cause signif-
icant induction of MCP-1 [3].
PKC was activated in mesangial cells using the phorbol ester,
phorbol 12-myristate 13-acetate (PMA, Sigma). [PMA increased
membrane bound PKC activity by 200 21% after 30 mm of
conditioning, measured using a PKC assay kit (GIBCO).] As a
control, the inactive phorbol, phorbol 12, 13-diacetate (Sigma)
was used to condition some monolayers. These were dissolved in
DMSO and diluted to achieve final concentrations of 1 to 1000
nM. Additionally, the effects of 1-oleoyl-2-acetylglycerol (Biomol,
Plymouth Meeting, Pennsylvania, USA), a membrane permeable
diacyiglycerol which activates PKC were studied. This was dis-
solved in ethanol and used at a final concentration of 10 or 100
nM. In other experiments mesangial PKC activity was inhibited
using the protein kinase inhibitor staurosporine (Sigma) in a
concentration range of 10 to 100 nM [19].
The cAMP-PKA pathway was also manipulated using inhibitors
and activators of this system. First, the effect of treating the cells
with H89 or KT5720 (Calbiochem, San Diego, California, USA),
competitive inhibitors of the catalytic subunit of PKA, on IL-i-
inducible MCP-i expression was examined. H89 was used at
concentrations of 0.1 to 30 j.LM, a range previously shown to be
effective in a variety of cultured cells [20,21]. We verified that H89
was active in mesangial cells in two ways. First the effect of H89 on
the induction of c-fos mRNA was examined. The expression of
c-fos is inducible by cAMP acting through PKA [22, 23]. In control
mesangial cells no c-fos message was detected; raising intracellu-
lar cAMP (see below for methods) induced c-fos mRNA within
one hour. This was prevented by treating the cells with H89 (25
j.M) for 30 minutes prior to inducing cAMP (data not shown).
PKA activity was also directly measured in mesangial cells after
intracellular cAMP was increased, using a PKA assay kit
(GIBCO). Raising intracellular cAMP caused PKA activity to
increase from a basal level of 24 4 pmol/min/mg cell protein to
477 16 pmol/min/mg (N = 4) after one hour. Pre-treating the
cells with H89 (10 M) caused a 61% reduction in cAMP-induced
PKA activity (182 24 pmol/min/mg). The final concentrations of
KT5720 (0.1 to 2 M) were equal to or greater than those reported
to be effective for other cells [20]. In mesangial cells a concentra-
tion of 0.5 LM reduced cAMP-stimulated PKA activity by approx-
imately 40% (282 1 pmol/min/mg).
Since the endogenous activator of PKA is known to be cAMP
[22—24], we also tested the effects of raising mesangial cell cAMP
on MCP-i expression. Intracellular cAMP was increased in two
ways. Cells were pre-incubated with 1 mrvi 3-isobutyl-1-methyl-
xanthine (IBMX, Sigma) a phosphodiesterase inhibitor, for 30
minutes. Twenty minutes into this pre-incubation, 20 m forskolin
(Sigma), an activator of adenylate cyclase, was added. These
reagents had no effect on mesangial cell viability as assessed by
tiypan blue exclusion or LDH release (Sigma LDH assay kit
#228-10). To confirm an adequate stimulation of cAMP, separate
monolayers were conditioned and intracellular cAMP measured
by specific RIA. This protocol increased intracellular cAMP
160-fold after 30 minutes (52 5.3 nvt stimulated vs. 0.3 0.05
flM basal, N = 3). The increase in cAMP was sustained for at least
four hours (44 1.3 n stimulated vs. 0.8 0.1 nM basal, N = 3).
Cells were also conditioned with the membrane permeable cAMP
analogues N6,2'-O-dibutyryladenosine 3' :5' -cyclic monophos-
phate (db-cAMP, Sigma) and 8-bromoadenosine 3':5'-cyclic
monophosphate (8-br-cAMP, Sigma). To provide a more effective
PKA stimulus, these analogues were used in combination at a
concentration of 1 m as previously described [20, 25].
The role of PTKs was evaluated by pre-treating mesangial cells
with the PTK inhibitors genistein (Calbiochem, 5 to 20 g/ml),
herbimycin A (GIBCO, 0.1 to 10 j.M), or tyrphostin B46 (Calbio-
chem, 10 to 50 M) [26—29]. (Cell viability was not adversely
effected by these inhibitors, measured by trypan blue exclusion
and LDH release.) The effect of these inhibitors on the induction
of MCP-i expression by IL-i was then assessed.
Control tissue culture media, media containing IL-i, the phor-
bol esters, and the organic solvents used in these experiments
were found to be virtually endotoxin free (<0.1 ng/ml) using the
quantitative Limulus amoebocyte lysate assay (M.A. Bioproducts,
Walkersville, Maryland, USA). In separate experiments it was
determined that endotoxin did not stimulate mesangial MCP-1
mRNA until the LPS concentration reached 1 .tWml. Thus it is
unlikely that endotoxin contributed to MCP-1 message levels in
this study.
Chemotaxis assay
The chemotactic activity of conditioned tissue culture superna-
tants was assessed by a modification of the method of Falk,
Goodwin and Leonard [30], using a 48-well microchemotaxis
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Fig. 1. Dose- and time-dependent expression of MCP-1
mRNA from PMA-treated mesangial cells. A. Northern blot
of mesangial RNA after conditioning the cells with 0, 1000,
10, 1 nM PMA for 4 hours (lanes 1—4 respectively) and 0 or
1000 nM PMA for 2 hours (lanes 5, 6 respectively). B.
Northern blot of mesangial RNA after conditioning the
cells with 10 tiM PMA for 0, 30, 90, 180 minutes (lanes 1—4
respectively). Both blots were reprobed for GAPD mRNA
to normalize for variations in RNA loading.
Fig. 2. Monocyte chemotactic activity from conditioned human mesangial
cells. Mesangial cells were exposed to media alone (CONT), IL-i (0.6
ng/ml), or PMA (10 nM) for 3 hours. The media was discarded, cells were
washed three times, and fresh media added. After 3 additional hours the
conditioned tissue culture supernatants were harvested and tested for
monocyte chemotactic activity. Mesangial cells treated with IL-i (*P <
0.001) or PMA (+P < 0.003) elaborated significantly more chemotactic
activity than control cells. Random migration was 2.3 0.6 cellslhpf.
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assembly (Neuroprobe, Cabin John, Maryland, USA) as previ-
ously described [3]. The tissue culture supernatants were har-
vested at a time point previously shown to give optimal superna-
tant chemotactic activity [3]. Responder cells were freshly isolated
human monocytes purified by the method of Graziano and Fanger
[31]. Typically the preparations were 78% monocytes (the rest
were lymphocytes) with a viability of 95%. Chemoattractant
activity was expressed as the number of monocytes that migrated
through the chemotaxis filter toward mesangial supernatants after
correcting for nonspecific migration. Nonspecific migration was
defined as the number of monocytes that migrated toward tissue
culture media that had not been exposed to mesangial cells.
MCP-1 ELISA
Antigenic MCP-1 was quantitated in the tissue culture super-
natants of mesangial cells using a double ligand ELISA technique
as originally described by Evanoff et a! [32]. Briefly, a specific
polyclonal goat anti-human MCP-1 antibody (R&D Systems,
Minneapolis, Minnesota, USA) was used as the capture antibody.
ELISA plates were coated with 50 .tl/well of the antibody at a final
concentration of 3 gIml. The same antibody was biotinylated
with NHS-LC-biotin (Pierce, Rockford, Illinois, USA) and used
as the detection antibody (50 .tl!well at a final concentration of 6
j.g/ml). The ELISA was developed by adding streptavidin-perox-
idase conjugate (Zymed, San Francisco, California, USA), fol-
lowed by OPD. The reaction was stopped by the addition of 3 M
H2S04 and the plates were read at 490 nm in an ELISA reader.
CONT IL-i PMA
conditions
The standard curve was made using human recombinant MCP-1
(PeproTech, Rocky Hill, New Jersey, USA). The standards were
added at concentrations of 1 pg/mI to 25 nglml (50 s.d/well). The
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Fig. 3. The effects of the PKC inhibitor staurosporine on IL-I and PMA -induced MCP-1 mRNA expression in human mesangial cells. Mesangial cells were
pre-incubated with staurosporine, 0, 10, 50, 100 nM (lanes 2—5 and 6—9, respectively) for 30 minutes. Lane one represents control cells with no further
additions. IL-i (lanes 2—5) or PMA (100 nM, lanes 6—9) was then added to each monolayer, and the incubation continued for 3 hours before RNA
harvest and Northern hybridization for MCP-1 mRNA. The blot was reprobed for GAPD mRNA to normalize for variations in RNA loading.
Fig. 4. The PKA inhibitor H89 does not prevent induction of MCP-1 mRNA by IL-i. Mesangial cells received media alone (lanes 1 and 2) or media
containing 0.1, 1, 10, or 30 .tM H89 (lanes 3—6, respectively) for 1 hour. IL-i (lanes 2—6) was then added. Control cells received no further additions
(lane 1). Total RNA was harvested after 2 hours and Northern analysis was used to measure MCP-1 mRNA. The blot was then reprobed for GAPD
mRNA to normalize for variations in RNA loading. Representative of 5 experiments.
linear detection range was 0.1 to 5 ng/ml. The ELISA was not
affected by the tissue culture media, and did not cross-react with
IL-i or PMA. To ensure specificity of the antibody, we also
performed Western blot analysis of tissue culture supernatants
from control, IL-i or PMA-treated mesangial cells. MCP-i was
not detected in supernatants from control cells. Supernatants
from IL-i or PMA-treated cells demonstrated two MCP-1 iso-
forms, consistent with the reported MCP-1 isoforms made by
other cell types [33, 34]. No other specific proteins were detected
in the PMA or IL-i-stimulated mesangial cells.
RNA isolation and Northern blot analysis
Total cellular RNA was isolated from 1 to 3 million mesangial
cells as previously described [35], by homogenizing the cells in 4 M
guanidinium thiocyanate (RNAzol-B, Cinn/Biotex, Friendswood,
Texas, USA), separating RNA from DNA and protein with
phenol-chloroform extraction, and recovering the RNA by isopro-
panol precipitation. RNA samples were washed with ethanol and
quantitated by absorbance a 260 nm. Approximately 10 to 15 .tg
of RNA was fractionated on a 1% agarose gel containing 1.8%
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Fig. 5. The effect of increasing intracellular
CAMP on basal and induced levels of MCP-1
mRNA. Mesangial cells were pre-incubated
in media alone (—) or media containing
IBMX + forskolin (+) for 30 minutes, as
described in Methods. IL-i or PMA (10 nM)
was then added. Control cells (C) received
no further additions. After 4 hours RNA
was isolated and Northern analysis for
MCP-1 mRNA was performed. The blot was
then reprobed for GAPD mRNA to
normalize for variations in RNA loading.
formaldehyde. The gels were stained with ethidium bromide to
confirm uniform RNA loading, and that there was no degradation
during processing. RNA was transferred to Hybond-N nylon
membranes (Amersham, Arlington Heights, Illinois, USA) by
overnight capillary action, and fixed by baking at 80°C for two
hours. The membranes were prehybridized at for at least 3 hours
and subsequently hybridized at 42°C for 20 hours in a solution
containing 50% formamide, 5x SSC, 1% SDS, 0.2% PVP, 0.2%
BSA, 0.2% Ficoll, and 150 ig/ml herring sperm DNA. Mem-
branes were washed twice in 2x SSC plus 0.2% SDS, and then in
0.2x SSC plus 0.1% SDS for 30 minutes at 56°C. Autoradiographs
of the blots were made using Kodak XAR-5 film (Eastman
Kodak, Rochester, New York, USA), and densitometry was
performed with an LKB laser densitometer (Pharmacia LKB
Biotechnology, Piscataway, New Jersey, USA). The resulting
values were used to calculate relative amounts of mRNA after
correcting for any discrepancies in RNA loading (see below).
MCP-1 mRNA was measured using a full length cDNA from
p-hHE34 (ATCC, Rockville, Maryland, USA [36]). The probes
were labeled with 32p-dCTP (3000 Ci/mmol) (New England
Nuclear, Boston, Massachusetts, USA), using a random primed
labeling kit (Boehringer-Mannheim, Indianapolis, Indiana, USA)
and the method of Feinberg and Vogeistein [37]. Blots were
subsequently re-probed for glyceraldehyde-3-phosphate dehydro-
genase (GAPD, Clonetech, Palo Alto, California, USA) to nor-
malize the amount of RNA in each lane.
Immunoblotting for lyrosine phosphoproteins
Confluent mesangial cells grown in 100 mm plates were treated
with media alone or media containing IL-i (0.6 nglml). At
specified times the cells were washed and disrupted in lysis buffer
(1% NP-40, 20 mivi Tris-HC1, pH 8.0, 137 mii NaC1, 10% glycerol,
1 m Na3VO4, 2 mpvi EDTA, 1 ifiM PMSF, 20 xM leupeptin, 0.15
U/ml aprotinin). The cell proteins (80 .tg) were resolved on a 10%
SDS-polyacrylamide gel under reducing conditions and trans-
ferred to 0.45 tm nitrocellulose membranes (Hoeffer, San Fran-
cisco, California, USA) using an electroblotting technique as
described by Kyhse-Anderson [38]. The membranes were probed
for tyrosine phosphoproteins using a specific anti-phosphoty-
Table 1. Effect of increasing intracellular cAMP on MCP-1 mRNA
levels in human mesangial cellsa
Experiment Control IL-i
IL-i +
cAMP' PMA
PMA +
cAMP"
1 1.2 12 0.4 7 0.2
2 0.8 15 3.4 10 1.4
3 0.7 9 0.4 4 0.5
Mean 0.9 12 1.4° 7 07d
SEM 0.2 2 1 2 0.4
a Data are expressed as densitometry area units.
"Intracellular cAMP was increased by pre-treating the cells with IBMX
and forskolin as described in Methods.
CP < 0.01 compared to IL-i alone
dP < 0.05 compared to PMA alone
rosine monoclonal antibody (clone 4Gb, UBI, Lake Placid, New
York, USA [39]), followed by a biotinylated rabbit anti-mouse
IgG (Zymed). The blots were developed using an ECL system
(Amersham). Specificity of the phosphotyrosine bands was veri-
fied by staining parallel blots as above, but substituting a non-
immune isotype control antibody for the primary antibody. Addi-
tionally, in some experiments 2 mrvi 1-phosphotyrosine was added
to the primary antibody solution to determine if this blocked
binding.
Statistical analysis
Data are presented as mean standard error. Data were
compared using a two tailed I-test (unpaired unless otherwise
noted). In the case of multiple comparisons, groups were com-
pared with one-way analysis of variance followed by the Bonfer-
roni post-test for multiple comparisons. A P < 0.05 was consid-
ered significant.
Results
PKC and MCP-1 expression
Human mesangial cells exposed to the PKC activating phorbol
ester PMA demonstrated a marked up-regulation of MCP-1 gene
expression. This was comparable to the message level induced by
C IL-i PMA
Rovin and Tan: MCP-1 regulation in mesangial cells 1063
1064 Rovin and Tan: MCP-1 regulation in mesangial cells
IL-i. In seven experiments, cells conditioned with 10 nM PMA for
3 to 4 hours showed an 11.4 3.0 fold increase in MCP-1 mRNA
over that of control mesangial cells (P < 0.02, paired t-test).
Analysis of seven additional monolayers concurrently treated with
0.6 ng/ml IL-i demonstrated a 17.4 4.3 fold increase in MCP-1
expression (P < 0.009, comparing IL-i-treated monolayers to
control monolayers using a paired t-test). MCP-1 mRNA in-
creased both as a function of PMA dose and duration of exposure
(Fig. 1). Other activators of PKC, such as the diacyiglycerol
1-oleyl-2-acetylglycerol (OAG), also induced MCP-1 mRNA
(cells treated with 10 or 100 nM OAG displayed a 10- or 6-fold
increase respectively in message compared to untreated cells).
Inactive phorbol esters such as phorbol 12,13-diacetate had no
effect on MCP-1 (data not shown).
In addition to inducing MCP-1 message, both PMA and IL-i
increased antigenic MCP-1 in mesangial cell supematants, as
measured by ELISA. Supernatants from untreated mesangial cells
had an MCP-1 level of 0.19 0.02 ng/ml (N = 6). Using cells
treated with IL-i (0.6 ng/ml) or PMA (10 nM) for three hours,
washed, and incubated for an additional four hours, the superna-
tant MCP-1 levels were found to be 4.2 0.6 ng/ml and 2.5 0.1
ng/ml (N = 3), respectively. Concomitant with the increase of
MCP-1 in mesangial supernatants, the monocyte chemotactic
activity of supernatants from mesangial cells treated with PMA or
IL-i increased significantly (Fig. 2). We have previously shown
that under these conditions 81% of the IL-i-induced monocyte
chemotactic activity from mesangial cells is due to MCP-1 [3].
Since activation of PKC mimicked the effects of IL-i, we sought
evidence that the actions of IL-i were mediated by PKC. Cells
were treated with the protein kinase inhibitor staurosporine
before the addition of IL-i. Staurosporine in concentrations up to
50 n had little effect on IL-i-induced MCP-1 expression (Fig. 3).
At a concentration of 100 nM, staurosporine caused a 34 9.6%
(N 5) decrease in IL-i induced message. In contrast, 10 nM
staurosporine reduced PMA-induced message by greater than
40%, and 50 to 100 nM staurosporine completely abrogated the
effects of PMA (Fig. 3).
The cAMP-PKA system and MCP-1 expression
To investigate the role of PKA in mediating the actions of IL-i,
we studied the effects of PKA inhibitors on MCP-i up-regulation
by IL-i. Th PKA inhibitor H89 did not prevent or reduce the
induction of MCP-1 mRNA by IL-i at concentrations of 0.1 to 30
LM (Fig. 4). As expected, PMA induction of MCP-i was not
attenuated by H89. Similar results were obtained with KT5720,
another competitive inhibitor of PKA, at concentrations of 0.1 to
2 jiM (data not shown). Consistent with the PKA inhibitor studies,
we found that agents which increased intracellular cAMP and
PKA activity did not reproduce the effects of IL-i on MCP-1
expression. On the contrary, raising cAMP by treating cells either
with forskolin plus IBMX, or the cell permeable cAMP analogues
db-cAMP plus 8-br-cAMP caused an 82% reduction in basal
levels of MCP-1 mRNA (0.62 0.2 vs. 0.11 0.04 densitometiy
area units, P < 0.04, N = 6; see also Fig. 5, lanes 1 and 2). This
result led us to investigate the effect of raising intracellular cAMP
on cytokine or phorbol-inducible MCP-i expression. As shown in
Figure 5, increasing intracellular cAMP with forskolin plus IBMX
completely prevented the up-regulation of MCP-1 mRNA by IL-i
or PMA. This was confirmed in several experiments (Table 1).
Inhibition could also be achieved with the cell permeable cAMP
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Fig. 6. The effect of raising intracellular cAMP on monocyte chemotactic
activity from human mesangial cells. Designated groups of mesangial cells(+cAMP) were pre-treated with IBMX and forskolin as described in
Methods. After 30 minutes IL-i (0.6 ng/ml) or PMA (10 nM) was added.
Control cells received no further additions. After 3 hours the media was
discarded, cells were washed 3 times, and fresh media added. The conditioned
tissue culture supernatants were harvested after an additional 3 hours and
tested for monocyte chemotactic activity. Supernatants from mesangial cells
treated with IL-i or PMA had significantly more chemotactic activity than
supernatants from control cells (*P < 0.01, N = 3). Raising intracellular
cAMP decreased the chemotactic activity induced by IL-i or PMA (+P <
0.01, N = 3). Random migration was 8.1 0.51 cells/hpf.
analogues db-cAMP plus 8-br-cAMP. IL-i and PMA-stimulated
MCP-i mRNA levels were reduced 46% and 84%, respectively, in
the presence of these analogues (data not shown). The actions of
cAMP on MCP-1 message did not represent a generalized
inhibition of RNA synthesis in mesangial cells. For example,
raising intracellular cAMP did not decrease the constitutive
expression of fibronectin mRNA or prevent the up-regulation of
decay accelerating factor mRNA by immune complex formation
on the mesangial cell surface [40, 41].
In addition to an inhibitory effect on MCP-1 mRNA expression,
raising intracellular cAMP completely prevented the increase in
supernatant chemotactic activity from mesangial cells conditioned
with IL-i (Fig. 6A), and reduced PMA-stimulated chemotactic
activity by 65% (Fig. 6B).
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Fig. 7. Dose dependent inhibition of IL-i-induced MCP-i
mRNA in mesangial cells by PTK inhibitors. Cells were pre-
treated with (A) genistein (sg/ml) for 15 minutes, (B)
herbimycin A (.tM) for 1 hour, or (C) tyrphostin B46 (M)
for 2 hours. IL-i was added for 2 hours. Control cells (C)
received no PTK inhibitors or IL-i. RNA was harvested
and analyzed for MCP-1 mRNA by Northern blotting. The
blots were then reprobed for GAPD mRNA to normalize for
variations in RNA loading. Representative of 2 to 4
experiments per condition.
PTKs and MCP-1 expression
To evaluate the role of PTKs in IL-i-induced MCP-1 up-
regulation, experiments to inhibit PTKs prior to treatment with
IL-i were conducted. As shown in Figure 7, three structurally
different PTK inhibitors, genistein, herbimycin A, and tyrphostiri
B46 each decreased IL-i-induced MCP-1 expression in a dose-
dependent fashion. Greater than 80 to 90% inhibition of IL-i-
induced MCP-1 message was achieved with genistein at a concen-
tration of 20 ig/ml, herbimycin A at a dose of 10 j.tM, or 50 M
tyrphostin. Supernatants from cells treated with genistein (20
p.g/ml) and IL-i had 65% less monocyte chemotactic activity than
supernatants treated with IL-i alone (8.1 2,2 vs. 22.6 1.5
monocytes migrated, respectively, P < 0.05, N =3). Genistein did
not attenuate PMA-induced chemotactic activity in mesangial
supernatants (data not shown).
These inhibitor studies suggested that the actions of IL-i may
be mediated by protein-tyrosine phosphorylation. We thus sought
evidence that IL-i could induce novel tyrosine phosphoproteins in
mesangial cells. Phosphotyrosine immunoblotting of cell lysates
from control or IL-i-treated mesangial cells demonstrated a
time-dependent increase in three tyrosine phosphoproteins with
approximate molecular masses of 43, 55, and 61 kD (Fig. 8).
Enhanced expression of these proteins was seen within 15 minutes
of IL-i-treatment, peaked by 30 minutes, and began to decline
after one hour. Immunoblotting demonstrated several tyrosine
phosphoproteins of higher molecular weight (greater than 80 kD),
that were constitutively present in mesangial cells and not influ-
enced by IL-i (not shown). The specificity of the primary antibody
was verified by substituting an isotype control antibody for the
anti-phosphotyrosine antibody, or by adding phosphotryosine (2
mM) to the anti-phosphotyrosine antibody. These modifications
completely blocked the appearance of the tyrosine phosphopro-
tein bands (data not shown).
Discussion
The intracellular mechanisms mediating the effects of IL-i on
MCP-i gene expression in human mesangial cells have not been
defined. Studies using other cell types have suggested that the
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Fig. 8. Time-dependent protein-lyrosine phosphorylation in IL-I-treated mesangial cells. Mesangial cells were unstimulated (0) or treated with IL-i (0.6
ng/ml) for the indicated lengths of time (minutes). Intracellular proteins were isolated, separated by PAGE, and transferred to nitrocellulose. Western
blotting was performed using a specific anti-phosphotyrosine monoclonal antibody. Relative positions of molecular weight markers (kD) are given.
Arrowheads indicate three tyrosine phosphoproteins upregulated by IL-i treatment. Representative of 3 experiments.
MCP-i gene may be regulated by PKC or cAMP-PKA [6, 7, 10,
42]. Although IL-i has been shown to stimulate protein phosphor-
ylation in mesangial cells [18], the responsible protein kinases
remain unknown. We postulated that a protein kinase pathway
activated by IL-i may be responsible for up-regulating MCP-1
gene expression in mesangial cells. This hypothesis was tested in
the present study. We found that the effects of IL-i are not
mediated by a staurosporine-sensitive PKC or the eAMP-PKA
system, but may be mediated by a PTK(s). The evidence may be
summarized as follows: (1) Direct activators of PKC (PMA or
diaeylglyeerol) caused induction of MCP-1 mRNA, secretion of
antigenic MCP-1, and mesangial-derived ehemotactic activity in a
fashion similar to IL-i. PKC inhibition by staurosporine com-
pletely blocked the effects of PMA. In contrast, staurosporine had
no effect on IL-i-induced gene activation at concentrations up to
50 n (19 times the reported IC50 for PKC [191), and only caused
a 34% inhibition at a high concentration (100 nm). (2) PICA
inhibitors did not abrogate the effects of IL-i, and increasing
intracellular cAMP, an activator of PICA, did not reproduce the
effects of IL-i, but rather inhibited constitutive and inducible
MCP-i expression. (3) PTK inhibitors blocked IL-i induction of
MCP-i mRNA and bioaetivity in a dose dependent fashion. (4)
IL-i induced three novel tyrosine phosphoproteins in mesangial
cells.
The finding that MCP-i gene expression in mesangial cells, like
that of endothelial and synovial cells, is up-regulated by activators
of PKC [7, 10], and is blocked by the PKC inhibitor staurosporine,
suggests that PKC may be important in the intracellular regula-
tion of MCP-i activity. A role for PKC is also implied by the
presence of a phorbol ester response element in the promoter
region of the MCP-i gene [5]. On the other hand, the inability of
the potent PKC inhibitor staurosporine to significantly attenuate
the effects of IL-i suggests that IL-i-induced MCP-i expression is
not mediated by PKC. [The small effect of high dose staurospo-
rine on IL-i-induced MCP-i message is likely to be secondary to
non-specific kinase inhibition, since staurosporine can block the
activity of other kinases (such as PTK) at high concentrations
[19].] The limitation of this analysis is that not all PKC isoforms
may be sensitive to a specific P1CC inhibitor [43, 44]. Thus, our
study does not exclude the possibility that IL-i may induce a
staurosporine-insensitive, novel PKC isoform. None the less, our
data are consistent with other studies that have suggested the
effects of IL-I on mesangial cells are independent of PKC [2, 16].
Stimulation of the cAMP-PKA system had an inhibitory effect
on MCP-1 expression, decreasing basal levels of MCP-1 mRNA
and blocking gene activation by both IL-i and PMA. There are
several examples of the cAMP-PKA system down-regulating gene
expression [45—47], including the recent observation that increas-
ing intracellular cAMP decreased MCP-1 gene transcription in
mouse mesangial cells [48]. In contrast to the data from mesangial
cells, cAMP has been reported to induce MCP-1 mRNA in
synovial cells and fibroblasts [7, 10]. The fact that cAMP appears
to have distinct effects on the expression of MCP-i in different
tissues suggests that this intracellular messenger may have an
important role in conferring tissue specificity to the inflammatory
response.
The PTK inhibitors genistein, herbimycin A, and tyrphostin B46
all effectively blocked IL-i-induced MCP-1 expression, suggesting
that the actions of IL-i may be transduced via a tyrosine phos-
phorylation step. This mechanism is further supported by the
finding that three tyrosine phosphoproteins in the 40 to 62 kD
molecular weight range were up-regulated in IL-i-treated me-
sangial cells. These data are consistent with the previously re-
ported finding that a 46 kD tyrosine phosphoprotein is induced in
rodent mesangial cells by IL-i [18]. Although further studies will
be necessary to characterize these IL-i-induced proteins, it is
interesting to note that the 43 kD protein falls within the
molecular weight range of the mitogen-activated protein (MAP)
kinases [49]. The MAP kinases require tyrosine phosphorylation
for activity, are putative signal transduction elements that can
regulate transcription factors, and may be induced by IL-i [50,
51]. It is intriguing to speculate that MAP kinases may be involved
in mediating some actions of IL-i in human mesangial cells.
In summary, IL-i up-regulation of mesangial MCP-l expression
as
0 5 15 30 60¶r
68
•
45
.4
36
Rovin and Tan: MCP-1 regulation in mesangial cells 1067
does not occur through a staurosporine-sensitive PKC or cAMP-
PKA signal transduction pathway. IL-i does appear to activate a
PTK(s) that may subsequently serve as an intracellular messenger
for gene activation. It is clear, however, that PKC activation can
stimulate mesangial MCP-1 expression. A PKC pathway may thus
be important for transducing the effects of inflammatory media-
tors other than IL-i. Additionally, our data do not exclude a role
for the cAMP-PKA system in MCP-1 regulation. Conceivably,
activation of this system may be an endogenous mechanism for
controlling glomerular monocyte infiltration. This study thus
illustrates several pathways which may be susceptible to interven-
tions designed to abrogate renal inflammation.
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